Opendata, web and dolomites

POLYBOOST

POLYBOOST: Renovating the Polyclonal Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 POLYBOOST project word cloud

Explore the words cloud of the POLYBOOST project. It provides you a very rough idea of what is the project "POLYBOOST" about.

revolutionize    disrupt    waited    commercial    polyclonals    society    customizing    clinicians    immunotherapy    death    stimuli    customized    influencing    autoimmune    turn    hiring    revenues    patients    doses    perspectives    fight    created    platform    diseases    full    organs    huge    financial    scarce    innovative    plan    immunosuppressants    move    life    registering    population    avantea    41    achievement    incidence    medicine    stimulate    cancer    transplantation    driving    chronic    views    believe    rejection    administered    safe    entering    rising    polyclonal    efficiency    damaged    severely    time    surgery    days    people    suppress    risk    prevent    medical    europeans    xenothera    retain    market    induce    organ    demand    immunological    progressive    significantly    benefits    effect    352    successful    immune    ageing    antigenicity    polyboost    severe    survival    proven    transplanted    safer    list    reducing    waiting   

Project "POLYBOOST" data sheet

The following table provides information about the project.

Coordinator
XENOTHERA 

Organization address
address: FACUKTE DE MEDECINE, 1 RUE GASTON VEIL
city: NANTES
postcode: 44035
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.xenothera.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    XENOTHERA FR (NANTES) coordinator 50˙000.00
2    AVANTEA srl IT (Cremona) participant 0.00

Map

 Project objective

Immunotherapy is an essential field of medicine that allows clinicians to stimulate or to suppress the response of our immune system against specific stimuli. The progressive ageing of the population and the rising incidence of chronic diseases is driving the demand for immunotherapy, as it can be used to fight cancer or autoimmune diseases. One of its major applications today is to prevent the rejection of transplanted organs. Since organs are scarce (40,000 Europeans on waiting list), patients are administered high doses of polyclonal immunosuppressants for several days around the time of surgery to prevent rejection. However, current polyclonals are not safe or reliable. Patients respond to these products by developing severe side effects that increase the risk for death & the medical costs. Thus, current polyclonals are only open for one time use. Also, the transplanted organ is severely damaged in the process, reducing its life-survival. In response, the consortium XENOTHERA & AVANTEA has created this project with the main objective of bringing to market a unique platform for the production of safer polyclonals (POLYBOOST). Our innovative method will revolutionize the field of immunotherapy, since it enables production of customized polyclonal products of low antigenicity, which retain a full immunological effect but do not induce side effects. We have proven the efficiency of POLYBOOST by customizing a polyclonal for transplantation medicine. In views of this successful achievement, we now aim to move forward towards the market. Thus, in Phase 1 we plan to assess all the aspects influencing the project from the technical, commercial and financial perspectives. We believe POLYBOOST will bring huge benefits for society and medicine, entering the market with a so long waited for product that will disrupt transplantation medicine. In turn, we expect the project to impact our growth significantly, registering €352 M in revenues and hiring 41 new people in 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POLYBOOST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "POLYBOOST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More